Male Infertility: Common Causes, Evaluation, and Treatment Options

1. Overview

Infertility is defined by the World Health Organization as the inability to achieve a clinically recognized pregnancy after 12 months of regular, unprotected sexual intercourse. Approximately 10–15 % of couples worldwide experience infertility, and male factors contribute to roughly half of these cases. Male infertility can result from a wide range of medical, environmental, and lifestyle factors that affect sperm production, function, or delivery. Understanding the underlying mechanisms, recognizing early signs, and seeking appropriate evaluation are essential steps toward effective management and, when possible, restoration of fertility.

2. Causes & Risk Factors

Male infertility is a multifactorial condition. The following categories summarize the most common etiologies, along with associated risk factors.

2.1. Testicular Disorders

• Varicocele: Dilatation of the pampiniform plexus veins in the scrotum; present in up to 15 % of men and up to 40 % of infertile men.
• Undescended Testes (Cryptorchidism): Failure of testicular descent during fetal development; increases risk of impaired spermatogenesis.
• Testicular Trauma or Surgery: Physical injury, orchiectomy, or procedures that disrupt the blood‑testis barrier.
• Testicular Cancer: Both the disease and its treatment (radiation, chemotherapy) can reduce sperm output.

2.2. Hormonal Imbalances

• Hypogonadotropic Hypogonadism: Low gonadotropin-releasing hormone (GnRH) or pituitary dysfunction leading to low luteinizing hormone (LH) and follicle‑stimulating hormone (FSH).
• Hyperprolactinemia: Elevated prolactin can suppress GnRH secretion.
• Thyroid Disorders: Both hypothyroidism and hyperthyroidism have been linked to altered sperm parameters.

2.3. Genetic Factors

• Klinefelter Syndrome (47,XXY): The most common chromosomal cause of male infertility.
• Y‑Chromosome Microdeletions: Deletions in AZF regions impair spermatogenesis.
• Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations: Associated with congenital bilateral absence of the vas deferens.

2.4. Obstructive Causes

• Ejaculatory Duct Obstruction: Congenital or acquired blockage preventing sperm passage.
• Vasectomy Reversal Complications: Incomplete recanalization may lead to low sperm counts.

2.5. Environmental and Lifestyle Influences

• Heat Exposure: Frequent use of hot tubs, saunas, or occupational heat (e.g., welders) can impair spermatogenesis.
• Radiation and Chemotherapy: Gonadotoxic agents damage rapidly dividing germ cells.
• Heavy Metals and Pesticides: Lead, cadmium, and certain organophosphates have been associated with reduced sperm quality.
• Smoking: Tobacco use is linked to decreased sperm concentration, motility, and morphology.
• Alcohol: Chronic excessive intake can alter hormone levels and sperm parameters.
• Obesity: Higher body mass index (BMI) correlates with lower testosterone and poorer semen quality.
• Recreational Drugs: Marijuana, anabolic steroids, and certain opioids may impair spermatogenesis.

2.6. Infectious Causes

• Sexually Transmitted Infections (STIs): Chlamydia trachomatis and Neisseria gonorrhoeae can cause epididymitis and scarring.
• Mumps Orchitis: Viral infection of the testes, especially in post‑pubertal males, can lead to permanent damage.

2.7. Idiopathic Infertility

In up to 30 % of cases, a definitive cause is not identified despite thorough evaluation. Ongoing research suggests subtle genetic or epigenetic factors may be involved.

3. Signs & Symptoms

Male infertility often presents without obvious symptoms, which is why many men are unaware of the problem until a partner experiences difficulty conceiving. When symptoms do appear, they may include:

• Pain, swelling, or a lump in the testicles or scrotum.
• Decreased facial or body hair (possible sign of hormonal deficiency).
• Reduced libido or erectile dysfunction (may indicate endocrine issues).
• History of prior testicular trauma, surgery, or infection.
• Physical findings such as a palpable varicocele.

Because many of these signs are nonspecific, a structured clinical evaluation is essential.

4. Prevention

• Maintain a healthy weight through balanced nutrition and regular physical activity.
• Avoid prolonged exposure to high temperatures (e.g., limit sauna sessions, avoid tight underwear that raises scrotal temperature).
• Quit smoking and limit alcohol consumption to moderate levels (≤ 2 drinks per day for men).
• Use protective equipment when handling chemicals, heavy metals, or radiation in occupational settings.
• Practice safe sex to reduce the risk of STIs; seek prompt treatment for infections.
• Limit recreational drug use, especially anabolic steroids and marijuana, which have been linked to reduced sperm quality.
• Schedule regular medical check‑ups, including hormonal screening if you have symptoms of hypogonadism.
• Consider genetic counseling if there is a known family history of chromosomal disorders or infertility.

5. Screening & Diagnosis

Evaluation of male infertility follows a stepwise approach that combines medical history, physical examination, laboratory testing, and imaging.

5.1. Medical History

• Duration of attempts to conceive.
• Past urologic or abdominal surgeries.
• History of infections, trauma, or exposure to toxins.
• Medication review (including over‑the‑counter supplements).
• Family history of infertility or genetic disorders.

5.2. Physical Examination

• Assessment of testicular size, consistency, and presence of varicocele.
• Evaluation of secondary sexual characteristics.
• Examination of the epididymis, vas deferens, and prostate.

5.3. Semen Analysis

The cornerstone of male fertility testing. According to the World Health Organization (WHO) 2021 reference values, normal parameters include:

• Volume ≥ 1.5 mL
• Sperm concentration ≥ 15 million/mL
• Total motile sperm count ≥ 39 million per ejaculate
• Progressive motility ≥ 32 %
• Normal morphology ≥ 4 % (strict criteria)

At least two samples collected 2–3 weeks apart are recommended to account for variability.

5.4. Hormonal Testing

• Serum FSH and LH – elevated levels may indicate primary testicular failure.
• Total testosterone – low levels suggest hypogonadism.
• Prolactin and thyroid‑stimulating hormone (TSH) – to rule out endocrine contributors.

5.5. Genetic Testing

• Karyotype analysis for chromosomal abnormalities (e.g., Klinefelter syndrome).
• Y‑chromosome microdeletion panel (AZF regions).
• CFTR mutation testing when congenital absence of the vas deferens is suspected.

5.6. Imaging Studies

• Scrotal ultrasonography – evaluates varicoceles, testicular lesions, and epididymal pathology.
• Transrectal ultrasound – assesses the seminal vesicles and ejaculatory ducts for obstruction.

5.7. Additional Tests

• Sperm DNA fragmentation assay – considered when conventional semen analysis is normal but infertility persists.
• Antisperm antibody testing – useful in cases of post‑vasectomy reversal or autoimmune concerns.

6. Treatment Options

Therapeutic strategies are individualized based on the identified cause, severity of semen abnormalities, and the couple’s reproductive goals. Options range from lifestyle modification to advanced assisted reproductive technologies (ART).

6.1. Lifestyle and Medical Management

• Varicocele Repair: Microsurgical varicocelectomy improves sperm concentration and motility in many men; guidelines recommend repair when a clinically significant varicocele coexists with abnormal semen parameters.
• Hormonal Therapy:
  • Clomiphene citrate or aromatase inhibitors may be used in hypogonadal men with preserved spermatogenesis.
  • Human chorionic gonadotropin (hCG) or recombinant FSH can stimulate sperm production in select cases of hypogonadotropic hypogonadism.
• Antibiotic Treatment: Targeted therapy for documented infections (e.g., chlamydia) can restore fertility if scarring has not occurred.
• Antioxidant Supplementation: Vitamins C and E, coenzyme Q10, and zinc have shown modest benefits in reducing oxidative stress‑related sperm damage, though evidence remains mixed.

6.2. Surgical Interventions

• Obstructive Repairs: Microsurgical reconstruction of the vas deferens (vasovasostomy) or epididymis (epididymovasostomy) following vasectomy or trauma.
• Testicular Sperm Extraction (TESE) / Microscopic TESE (mTESE): Retrieval of sperm directly from testicular tissue for use in ART, particularly in non‑obstructive azoospermia.

6.3. Assisted Reproductive Technologies

• Intrauterine Insemination (IUI): Processed sperm is placed directly into the uterus; suitable when sperm count and motility are moderately reduced.
• In Vitro Fertilization (IVF) with Conventional IVF: Fertilization occurs in the laboratory; indicated when sperm parameters are adequate but other factors (e.g., tubal disease) exist.
• Intracytoplasmic Sperm Injection (ICSI): A single sperm is injected directly into an oocyte; the preferred method for severe oligozoospermia, asthenozoospermia, teratozoospermia, or when sperm are retrieved surgically.

Success rates for ICSI range from 40–60 % per cycle, depending on female age and embryo quality, according to recent reproductive medicine guidelines.

6.4. Emerging Therapies

• Stem Cell Research: Investigations into spermatogonial stem cell transplantation aim to restore fertility after gonadotoxic therapy, though clinical application remains experimental.
• Gene Editing: CRISPR‑based approaches are being explored for specific genetic defects, but ethical and safety considerations limit current use.

7. Myths vs Facts

8. When to See a Doctor

Prompt evaluation is recommended in the following situations:

• Failure to achieve pregnancy after 12 months of regular, unprotected intercourse (or 6 months if the female partner is over 35 years).
• History of testicular trauma, surgery, or infection.
• Noticeable changes in testicular size, pain, or a palpable mass.
• Symptoms of hormonal imbalance such as reduced libido, erectile dysfunction, or loss of secondary sexual characteristics.
• Exposure to known gonadotoxic agents (chemotherapy, radiation, heavy metals).
• Prior diagnosis of a genetic condition associated with infertility.

Early referral to a urologist or reproductive endocrinologist can streamline diagnosis and improve treatment outcomes.

Conclusion

Male infertility is a common, complex condition that affects a significant proportion of reproductive‑age couples. A systematic approach—starting with a detailed history, focused physical examination, and comprehensive laboratory testing—allows clinicians to identify reversible causes, guide appropriate therapy, and refer for assisted reproductive technologies when needed. Lifestyle modification, treatment of underlying medical conditions, and, when indicated, surgical or ART interventions can substantially improve the likelihood of achieving a successful pregnancy. Ongoing research continues to expand our understanding of genetic and molecular contributors, offering hope for more personalized therapies in the future.